Aprea Therapeutics (APRE) Operating Income (2022 - 2026)
Aprea Therapeutics (APRE) posted quarterly Operating Income of -$3.4 million for Q1 2026, up 16.04% year-over-year from -$3.0 million in Q1 2025, and down 29.79% quarter-over-quarter from -$2.6 million in Q4 2025.
Aprea Therapeutics (APRE) Operating Income (2022 - 2026) Analysis & Trends
Aprea Therapeutics (APRE) has reported Operating Income for 5 consecutive years, with -$3.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Income rose 16.04% year-over-year to -$3.4 million; the TTM figure through Mar 2026 stood at -$12.6 million (up 17.55% YoY), while the FY2025 annual figure was -$13.2 million, up 7.58% from the prior year.
- Operating Income fell to -$3.4 million in Q1 2026 per APRE's latest filing, from -$2.6 million in the prior quarter.
- Across five years, Operating Income topped out at -$2.6 million in Q4 2025 and bottomed at -$98.5 million in Q2 2022.
- Historically, Operating Income has averaged -$9.5 million across 5 years, with a median of -$3.6 million in 2023.
- On a YoY basis, Operating Income climbed as much as 96.29% in 2023 and fell as far as 38.59% in 2023.
- Aprea Therapeutics' Operating Income stood at -$2.7 million in 2022, then plunged by 38.59% to -$3.7 million in 2023, then climbed by 12.21% to -$3.2 million in 2024, then gained by 18.07% to -$2.6 million in 2025, then fell by 29.79% to -$3.4 million in 2026.
- Business Quant data shows APRE's Operating Income at -$3.4 million in Q1 2026, -$2.6 million in Q4 2025, and -$3.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Aprea Therapeutics | 34.28 Mn | 34.28 Mn | - | -4.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.03 Mn |
| Mar 31, 2026 | -3.43 Mn |
| Dec 31, 2025 | -2.64 Mn |
| Sep 30, 2025 | -3.12 Mn |
| Jun 30, 2025 | -3.39 Mn |
| Mar 31, 2025 | -4.09 Mn |
| Dec 31, 2024 | -3.23 Mn |
| Sep 30, 2024 | -4.10 Mn |
| Jun 30, 2024 | -3.85 Mn |
| Mar 31, 2024 | -3.15 Mn |
| Dec 31, 2023 | -3.67 Mn |
| Sep 30, 2023 | -3.52 Mn |
| Jun 30, 2023 | -3.65 Mn |
| Mar 31, 2023 | -4.62 Mn |
| Dec 31, 2022 | -2.65 Mn |
| Sep 30, 2022 | -4.20 Mn |
| Jun 30, 2022 | -98.47 Mn |